| Entry |
|
|---|
| Name |
Vurolenatide (USAN/INN) |
|---|
| Formula |
C3356H5183N915O1575S
|
|---|
| Exact mass |
83532.3325
|
|---|
| Mol weight |
83579.30
|
|---|
| Sequence |
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPSG GSPAGSPTST EEGTSESATP
ESGPGTSTEP SEGSAPGSPA GSPTSTEEGT STEPSEGSAP GTSTEPSEGS APGTSESATP
ESGPGSEPAT SGSETPGSEP ATSGSETPGS PAGSPTSTEE GTSESATPES GPGTSTEPSE
GSAPGTSTEP SEGSAPGSPA GSPTSTEEGT STEPSEGSAP GTSTEPSEGS APGTSESATP
ESGPGTSTEP SEGSAPGTSE SATPESGPGS EPATSGSETP GTSTEPSEGS APGTSTEPSE
GSAPGTSESA TPESGPGTSE SATPESGPGS PAGSPTSTEE GTSESATPES GPGSEPATSG
SETPGTSESA TPESGPGTST EPSEGSAPGT STEPSEGSAP GTSTEPSEGS APGTSTEPSE
GSAPGTSTEP SEGSAPGTST EPSEGSAPGS PAGSPTSTEE GTSTEPSEGS APGTSESATP
ESGPGSEPAT SGSETPGTSE SATPESGPGS EPATSGSETP GTSESATPES GPGTSTEPSE
GSAPGTSESA TPESGPGSPA GSPTSTEEGS PAGSPTSTEE GSPAGSPTST EEGTSESATP
ESGPGTSTEP SEGSAPGTSE SATPESGPGS EPATSGSETP GTSESATPES GPGSEPATSG
SETPGTSESA TPESGPGTST EPSEGSAPGS PAGSPTSTEE GTSESATPES GPGSEPATSG
SETPGTSESA TPESGPGSPA GSPTSTEEGS PAGSPTSTEE GTSTEPSEGS APGTSESATP
ESGPGTSESA TPESGPGTSE SATPESGPGS EPATSGSETP GSEPATSGSE TPGSPAGSPT
STEEGTSTEP SEGSAPGTST EPSEGSAPGS EPATSGSETP GTSESATPES GPGTSTEPSE
GSAPG |
|---|
| Type |
Peptide |
|---|
| Class |
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
|
|---|
| Efficacy |
Glucagon-like peptide 1 (GLP-1) receptor agonist |
|---|
| Comment |
Treatment of Short bowel syndrome
|
|---|
| Target |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
D12341 Vurolenatide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP1R
D12341 Vurolenatide (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
